We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Maintenance Treatment With Long-Acting Injectable Antipsychotics Comparing Old With New

Donald C. Goff, MD1,2,3
[+] Author Affiliations
1Nathan Kline Institute for Psychiatric Research
2New York University School of Medicine
3Associate Editor, JAMA
JAMA. 2014;311(19):1973-1974. doi:10.1001/jama.2014.4311.
Text Size: A A A
Published online


Prevention of relapse is a major challenge in the treatment of schizophrenia. The re-emergence of psychosis, characterized by delusions, hallucinations, and disorganization, can be dangerous, disruptive, and costly for patients and their families. The risk of relapse is increased by factors commonly encountered in this group of patients, such as poor adherence, substance use, and social stress. High rates of nonadherence with antipsychotics, estimated at 40%, reflect an unfavorable balance between adverse effects and perceived benefit. Cognitive deficits, combined with poor social supports and homelessness, also can complicate adherence with daily dosing of oral medication. Long-acting injectable formulations of antipsychotics, which maintain therapeutic blood levels during the 2- to 4-week interval between injections, were developed to counter the problem of nonadherence; studies conducted in the 1980s of long-acting injectable preparations of fluphenazine, a first-generation antipsychotic, generally found a reduction in relapse rates.1

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Pharmacologic Management

Care at the Close of Life: Evidence and Experience
Typical Antipsychotic Medications